Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).

被引：0

作者：

Leleu, Xavier P.

Hulin, Cyrille

Lambert, Jerome

Bobin, Arthur

Manier, Salomon

Perrot, Aurore

Jaccard, Arnaud

Montes, Lydia

Karlin, Lionel

Godmer, Pascal

Chalopin, Thomas

Slama, Borhane

Laribi, Kamel

Chretien, Marie-Lorraine

Mohty, Mohamad

Touzeau, Cyrille

Moreau, Philippe

Avet-Loiseau, Herve

Corre, Jill

Facon, Thierry

机构：

[1] Univ Poitiers, INSERM U1313, Poitiers, France

[2] Ctr Hosp Univ Poitiers, INSERM, Poitiers, France

[3] CIC 1082, Poitiers, France

[4] Univ Hosp, H op Haut Leveque, Pessac, France

[5] ECSTRA, Ctr Rech Epidemiol & Stat, INSERM UMR 1153, Paris, France

[6] Lille Univ Hosp, Lille, France

[7] Univ Toulouse, Serv Hematol, CHU Toulouse, IUCT O,UPS, Toulouse, France

[8] CHU Limoges, Limoges, France

[9] CHU Amiens, Amiens, France

[10] Ctr Hosp Lyon Sud, Dept Urol, Pierre Benite, France

[11] GHBA, Vannes, France

[12] CHU Tours, Tours, France

[13] CH Avignon, Avignon, France

[14] Ctr Hosp Le Mans, Dept Hematol, Le Mans, France

[15] CHU Dijon, Dijon, France

[16] Sorbonne Univ, Hop St Antoine, APHP, Paris, France

[17] Univ Nantes, Hotel Dieu Hosp Ctr, Nantes, France

[18] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[19] IUCT Oncopole, Unit Genom Myeloma, INSERM U1037, Toulouse, France

[20] Univ Canc Inst IUCT Oncopole, Dept Hematol, Toulouse, France

[21] Hop Claude Huriez, Lille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7501

引用

页数：1